| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Published online before print May 8, 2008
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




From the Departments of Pathology,* Virology I,
and Virology III,
National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan
Advanced age is a risk factor of severe acute respiratory syndrome (SARS) in humans. To understand its pathogenesis, we developed an animal model using BALB/c mice and the mouse-passaged Frankfurt 1 isolate of SARS coronavirus (SARS-CoV). We examined the immune responses to SARS-CoV in both young and adult mice. SARS-CoV induced severe respiratory illness in all adult, but not young, mice on day 2 after inoculation with a mortality rate of 30 to 50%. Moribund adult mice showed severe pulmonary edema and diffuse alveolar damage accompanied by virus replication. Adult murine lungs, which had significantly higher interleukin (IL)-4 and lower IL-10 and IL-13 levels before infection than young murine lungs, rapidly produced high levels of proinflammatory chemokines and cytokines known to induce macrophage and neutrophil infiltration and activation (eg, tumor necrosis factor-
). On day 2 after inoculation, young murine lungs produced not only proinflammatory cytokines but also IL-2, interferon-
, IL-10, and IL-13. Adult mice showed early and acute excessive proinflammatory responses (ie, cytokine storm) in the lungs after SARS-CoV infection, which led to severe pulmonary edema and diffuse alveolar damage. Intravenous injection with anti-tumor necrosis factor-
antibody 3 hours after infection had no effect on SARS-CoV infection. However, intraperitoneal interferon-
injection protected adult mice from the lethal respiratory illness. The experimental model described here may be useful for elucidating the pathophysiology of SARS and for evaluating therapies to treat SARS-CoV infection.
This article has been cited by other articles:
![]() |
T. A. Miura and K. V. Holmes Host-pathogen interactions during coronavirus infection of primary alveolar epithelial cells J. Leukoc. Biol., November 1, 2009; 86(5): 1145 - 1151. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Wohlford-Lenane, D. K. Meyerholz, S. Perlman, H. Zhou, D. Tran, M. E. Selsted, and P. B. McCray Jr. Rhesus Theta-Defensin Prevents Death in a Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Pulmonary Disease J. Virol., November 1, 2009; 83(21): 11385 - 11390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Khanolkar, S. M. Hartwig, B. A. Haag, D. K. Meyerholz, L. L. Epping, J. S. Haring, S. M. Varga, and J. T. Harty Protective and Pathologic Roles of the Immune Response to Mouse Hepatitis Virus Type 1: Implications for Severe Acute Respiratory Syndrome J. Virol., September 15, 2009; 83(18): 9258 - 9272. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Khanolkar, S. M. Hartwig, B. A. Haag, D. K. Meyerholz, J. T. Harty, and S. M. Varga Toll-Like Receptor 4 Deficiency Increases Disease and Mortality after Mouse Hepatitis Virus Type 1 Infection of Susceptible C3H Mice J. Virol., September 1, 2009; 83(17): 8946 - 8956. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |